Volume : 09, Issue : 12, December – 2022
Title:
08.OVERVIEW; PUBLIC HEALTH APPROACH TOWARD ACUTE LIVER FALIUR AND ITS MANAGEMENT
Authors :
MOHAMMED EID ALHARBI, ABDULKARIM JAMAAN MUHAWWIS ALBIJALI, AHMED ABDULLAH HASANAIN, SHUAIB SHABAAN ALZAHRANI, Abdulrahman Tami Almuntashri, Menwer Mohsen Mubarak Alfahmi, ALOFI, ADIL SALEH S, TURKI MARZOUQ OSIKER ALOTABI, ABDULMAJEED HASSAN MOHAMMED ALBARAKATI,SAAD KHALF ALLAH OTAYF ALZAHRANI
Abstract :
The purpose of this review was to assess the most recent information about the treatment of acute liver failure (ALF) and to explain the diagnostic strategies that will identify the appropriate treatment for ALF. We evaluate the most recent studies on approaches to acute liver failure, as well as those papers that were published prior to March, 2022. The Midline (PubMed) and Embase databases were searched for papers pertinent to our topic of interest, and then evidence was carefully gathered from each study in order to conduct this review as an up-to-date assessment of all ALF therapy options. Severe liver failure is associated with quickly progressing multiorgan failure and catastrophic complications; nevertheless, emergency liver transplantation has improved patient outcomes. A practice-based evidence base is growing for supportive therapy, and a better knowledge of the pathophysiology of the illness, particularly as it relates to hepatic encephalopathy, will likely lead to additional increases in survival rates in the near future. According to additional research, liver transplantation is the only option with a survival benefit. Liver assist devices and hepatocyte transplantation are still experimental, and additional progress is required. Controlling hepatitis A, B, E, and drug-induced liver injury will reduce the incidence and mortality of ALF.
Cite This Article:
Please cite this article in press Mohammed Eid Alharbi et al, Overview; Public Health Approach Toward Acute Liver Failure And Its Management.., Indo Am. J. P. Sci, 2022; 09(12).
Number of Downloads : 10
References:
2. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197.
3. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007; 102: 2459–63.
4. Brandsaeter B, Hockerstedt K, Friman S, et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation—12 years experience in the nordic countries. Liver Transpl 2002; 8: 1055–62.
5. Escorsell A, Mas A, de la Mata M, and the Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007; 13: 1389–95.
6. Stravitz RT, Kramer DJ. Management of acute liver failure. Nat Rev Gastroenterol Hepatol. 2009;6:542–553.
7. Kumar R, Shalimar, Bhatia v, et al. Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome. Hepatology. 2010;51:1665–1674.
8. Shiffman ML. Management of acute hepatitis B. Clin Liver Dis. 2010;14:75–91.
9. Shukla NB, Poles MA. Hepatitis B infection: co-infection with hepatitis C virus, hepatitis D virus and human immunodeficiency virus. Clin Liver Dis. 2004;8:445–460.
10. Sagnelli E, Coppola N, Pisaturo M, et al. HBv superinfection in HCv chronic carriers: a disease that is frequently severe but associated with the eradication of HCv. Hepatology. 2009;49:1090–1097.
11. chai P, Samuel D. Etiology and prognosis of fulminant hepatitis in adults. Liver Transpl. 2008;14(suppl 2):S67–79.
12. U.S. Department of Health & Human Services. OPTN: Organ Procurement and Transplantation Network . Available at: http://optn.transplant.hrsa.gov/latestdata/rptdata.asp.
13. Mas A, Rodes J. Fulminant hepatic failure. Lancet. 1997;349:1081–1085.
14. Ostapowicz G, Fontana RJ, SchiØdt Fv, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954.
15. Fong TL, Klontz KC, Canas-Coto A, et al. Hepatotoxicity due to hydroxycut: a case series. Am J Gastroenterol. 2010 Jan 26; [Epub ahead of print]
16. Gloro R, Hourman-Olivier I, Mosquet B, et al. Fulminant hepatitis during self medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol. 2005;17:1135–1137.
17. Ganzert M, Felgenhauer N, Zilker T. Reassessment of predictors of fatal outcome in amatoxin poisoning: some critical comments. J Hepatol. 2007;47:424–425.
18. Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology. 2009;137:856–864.
19. McDowell Torres D, Stevens RD, Gurakar A. Acute Liver Failure: A Management Challenge for the Practicing Gastroenterologist. Gastroenterology & Hepatology. 2010;6(7):444-450.
20. Bernal W, Wendon J. Acute liver failure. N Engl J Med. 2013;369:2525–34.
21. Lee WM. Acute liver failure. Semin Respir Crit Care Med. 2012;33:36–45.
22. Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102:2459–63.
23. Stravitz RT, Kramer AH, Davern T, Shaikh AO, Caldwell SH, Mehta RL, et al. Intensive care of patients with acute liver failure: Recommendations of the U.S. acute liver failure study group. Crit Care Med. 2007;35:2498–508
24. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976-1985) N Engl J Med. 1988;319:1557–62.
25. Siniscalchi A, Dante A, Spedicato S, Riganello L, Zanoni A, Cimatti M, et al. Hyperdynamic circulation in acute liver failure: Reperfusion syndrome and outcome following liver transplantation. Transplant Proc. 2010;42:1197–9.
26. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: Therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953–5.
27. Miyake Y, Iwasaki Y, Takaki A, Fujioka S, Takaguchi K, Ikeda H, et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med. 2008;47:1293–9.
28. Escudié L, Francoz C, Vinel JP, Moucari R, Cournot M, Paradis V, et al. Amanita phalloides poisoning: Reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol. 2007;46:466–73.
29. Korman JD, Volenberg I, Balko J, Webster J, Schiodt FV, Squires RH, Jr, et al. Screening for Wilson disease in acute liver failure: A comparison of currently available diagnostic tests. Hepatology. 2008;48:1167–74.
30. Joshi D, James A, Quaglia A, Westbrook RH, Heneghan MA. Liver disease in pregnancy. Lancet. 2010;375:594–605.
31. Scott TR, Kronsten VT, Hughes RD, Shawcross DL. Pathophysiology of cerebral oedema in acute liver failure. World J Gastroenterol. 2013;19:9240–55.
32. Wang DW, Yin YM, Yao YM. Advances in the management of acute liver failure. World J Gastroenterol. 2013;19:7069–77. [
33. Pyleris E, Giannikopoulos G, Dabos K. Pathophysiology and management of acute liver failure. Ann Gastroenterol. 2010;23:257–65.
34. Shawcross DL, Wendon JA. The neurological manifestations of acute liver failure. Neurochem Int. 2012;60:662–71.
35. Vaquero J, Fontana RJ, Larson AM, Bass NM, Davern TJ, Shakil AO, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11:1581–9.
36. Larsen FS, Murphy N, Bernal WL. Prophylactic effect of mild hypothermia to prevent brain edema in patients with acute liver failure: Results of a multicenter, randomized, controlled trial. J Hepatol. 2011;54:S26.
37. Acharya SK, Dasarathy S, Kumer TL, Sushma S, Prasanna KS, Tandon A, et al. Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome. Hepatology. 1996;23:1448–55.
38. Lee WM, Stravitz RT, Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology. 2012;55:965–7